Fulcrum licenses CAMP4's Diamond Blackfan Anemia program for up to $70M in milestones plus royalties

Fulcrum Therapeutics, Inc.

• Exclusive worldwide license to CAMP4's DBA program, including small molecule compounds and patent rights.
• Undisclosed upfront payment; up to $35M in development/regulatory milestones and $35M in sales milestones.
• Royalties on net sales: mid-single to low-double digit, subject to reductions for patent loss or generics.
• Fulcrum responsible for all development and regulatory costs; CAMP4 may terminate for non-payment or patent challenges.
• License expires per product/country upon later of patent expiry, regulatory exclusivity end, or 10 years after first sale.